Author:
Илиева И. Н.,Саинова И. В.,Тошкова Р. А.,Георгиева А. К.,Нанев В. Н.,Цонева Р. Д.
Abstract
Aim. The goal of the current study is directed to investigate the therapeutic effect of erufosine (ЕРС3) alone, as well as in combination with doxorubicin (DOX) on the development of metastases in the testes in an experimental model of transplantable Graffi myeloid tumor (GMT) in hamsters.
Materials & Methods. Experimental in vivo model of GMT in Golden Syrian hamsters was used. Animals were inoculated subcutaneously with live virus-transformed malignant cells. Testes from male tumor-bearing hamsters (TBHs), treated and non-treated with the antitumor agent erufosine alone or in combination with DOX, as well as untreated healthy controls, were subjected to morphometric and histological assays on the testicular architecture to evaluate potential antitumor/antimetastatic effects in in vivo conditions.
Results. The results showed no changes in blood vessels and morphology (impaired spermatogenesis and/or metastatic changes) of the testicular tissue in TBHs treated with antitumor agents (alone or in combination) compared to control healthy animals. In contrast, in the testes of TBHs without therapy, impaired spermatogenesis and foci of metastases, as well as significant changes in testicular blood vessels were found.
Conclusion. The data obtained demonstrated an antitumor/antimetastatic effect of EPC3 in the testes of hamsters in the experimental GMT model.
Publisher
Practical Medicine Publishing House